NCT02965326View on ClinicalTrials.gov

Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

March 31, 2026

Study Completion Date

October 31, 2026

Conditions

Cystic Fibrosis

Interventions

PROCEDURE

Nasal swab; rectal biopsy.

Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.

Trial Locations (1)

75014

RECRUITING

Necker Hospital, Paris

All Listed Sponsors

collaborator

Association Mucoviscidose-ABCF2

OTHER

collaborator

Vaincre la Mucoviscidose

OTHER

lead

Hôpital Necker-Enfants Malades

OTHER

NCT02965326 - Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients | Biotech Hunter | Biotech Hunter